MERCANS
Avasant, a globally recognized analyst firm, has named Mercans as a payroll process transformation leader in its annual RadarView assessment of 2022-2023. Mercans clearly stood out among the 27 providers assessed for consistently delivering exceptional value to the market. Avasant's comprehensive industry analysis categorizes providers into challengers, disruptors, innovators, and leaders. Avasant placed Mercans in an elite group of industry leaders, confirming its technology leadership role in the global payroll industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231222991924/en/
Mercans Emerges as a Payroll Business Process Transformation Leader in Avasant's RadarView (Photo: AETOSWire)
In a span of one year, Mercans transitioned from a disruptor to an industry leader in Avasant’s assessment, demonstrating its impressive progress across all RadarView’s critical excellence dimensions - practice maturity, domain ecosystem, and investments and innovation.
Avasant's meticulous research methodology, incorporating publicly available information, SEC filings, annual reports, executive interviews, product demos, and direct inputs from service providers, adds depth and credibility to the acknowledgment of Mercans' industry leadership.
Avasant highlights Mercans' strategic approach and states: Leveraging its proprietary payroll engine and in-house local experts, Mercans delivers services across 160 countries. Mercans boasts a distinctive practice size, serving multinational corporations and Fortune 500 companies, supporting over 40 languages. The company's global delivery infrastructure spans 121 local offices, contributing to an impressive payroll revenue growth of over 30% from June 2022 to June 2023, reflecting its financial robustness.
At the heart of Mercans' success lies its proprietary global payroll platform - HR Blizz, the only gross-to-net payroll application that allows generating statutory compliant payrolls worldwide in a single software.
Mercans has disrupted the global payroll landscape with its G2N Nova global payroll engine. This state-of-the-art payroll engine stands out as the sole stateless application globally, swiftly generating payroll calculations across 160 countries within seconds, all while avoiding the storage of any sensitive employee data. This innovative approach has positioned G2N Nova as a catalyst for multinational corporations seeking to fully digitize their global payroll operations. Beyond its uniqueness as the sole global gross-to-net payroll application, G2N Nova offers a fully autonomous and touchless payroll experience, leading to dramatic reductions in processing times and costs.
Aditya Jain, Principal Analyst at Avasant, comments, "Mercans has developed its native global payroll engine to facilitate gross-to-net payroll calculations, digitalize processes, and offer self-service functionality to employees in 160 countries worldwide. Its partnerships with HCM and ancillary HR platform vendors enable it to offer comprehensive HR services through a unified portal. It leverages its local delivery network, including offices and regional experts in 121 countries, to help enterprises reduce dependence on local payroll aggregators for last-mile services across countries.
"Its continued investments in technology innovation, such as no-code HR integration tools and instant payments functionality, flexible business models, and a global delivery network, have made Mercans a leader in Avasant’s Payroll Business Process Transformation 2023–2024 RadarView."
About Mercans
Mercans is a global leader in payroll technology. Mercans’ revolutionary global payroll platform HR Blizz enables SMBs and enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.
Visit www.mercans.com
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231222991924/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom